Understanding KRAS G12C in NSCLC

This episode of Lung Cancer Considered covers recent promising results with new targeted agents for NSCLC harboring a KRAS G12C mutation. Thoracic oncologists have long thought this condition was undruggable, but results presented at WCLC 2020 from the CodeBreak 100 trial provide hope that new therapies will be more readily available.